Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01201928 · ClinicalTrials.gov registry record

Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166

A clinical trial, sponsored by Mannkind Corporation.

Terminated
Registry status
3
Enrollment target

NCT01201928: Clinical Trial study, sponsored by Mannkind Corporation.

NCT01201928 is a clinical trial that was terminated before completion, run by Mannkind Corporation. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01201928 was terminated before completion, sponsored by Mannkind Corporation.

TERMINATED
Registry status
3 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate pulmonary function test (PFT) sub-study in interested subjects from studies MKC-TI-161, MKC-TI-162 and MKC-TI-166. 100 Type I and 100 Type II diabetics will be enrolled. Each subject will undergo 6 PFT assessments over the course of the parent study.

Interventions

  • DRUG Technosphere Insulin Inhalation Powder
  • DRUG Comparator administered in parent trial

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2010-10
Est. Completion 2012-03
Mannkind Corporation

42 total trials

Why NCT01201928 stopped before completion

NCT01201928 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.

The record links to 0 conditions, and to 2 interventions - of which Technosphere Insulin Inhalation Powder is the first listed.

NCT01201928 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01201928 about?

NCT01201928 is a clinical study titled "Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166". The purpose of this study is to evaluate pulmonary function test (PFT) sub-study in interested subjects from studies MKC-TI-161, MKC-TI-162 and MKC-TI-166. 100 Type I and 100 Type II diabetics will be enrolled. Each subject will undergo 6 PFT assessments over the course of the parent study.

What is the current status of trial NCT01201928?

This trial is currently terminated. The enrollment target is 3 participants. The study started on 2010-10. Estimated completion is 2012-03.

What interventions are being tested in trial NCT01201928?

The interventions under investigation include: Technosphere Insulin Inhalation Powder (DRUG), Comparator administered in parent trial (DRUG).

Who is sponsoring clinical trial NCT01201928?

This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01201928, the US trial registry maintained by the National Library of Medicine. NCT01201928 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.